文献速递神经康复

西酞普兰对急性缺血性卒中结局的疗效:一项随机临床试验

Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial.
PubMed 文献 · Neurorehabil Neural Repair · 2017-04-28

这项随机安慰剂对照试验纳入144例非抑郁急性缺血性卒中患者,比较口服西酞普兰20 mg每日一次与安慰剂治疗3个月的结局。西酞普兰组79%达到主要结局(3个月NIHSS评分较基线下降50%),安慰剂组为54%(P < .001),风险比2(CI = 1.2-3),需治疗人数4(CI = 2.5-8.6),两组均未发现重大不良事件。

要点

  • 西酞普兰20 mg每日一次可提高急性缺血性卒中3个月神经功能改善达标率。
  • 主要结局达标率西酞普兰组79% vs 安慰剂组54%,P < .001。
  • 风险比2(CI = 1.2-3),需治疗人数4(CI = 2.5-8.6),两组无重大不良事件。

核心结论

  • 西酞普兰在急性缺血性卒中患者中安全且耐受性良好,可能改善这些患者的结局。

研究设计与样本

  • 随机、安慰剂对照临床试验,纳入144例急性缺血性卒中患者,研究为期3个月。
  • 西酞普兰组口服西酞普兰20 mg每日一次,安慰剂组接受安慰剂,所有患者均接受包括物理治疗在内的标准治疗。
  • 研究全程排除抑郁患者,主要结局为3个月美国国立卫生研究院卒中量表评分较基线下降50%。

主要发现

  • 144例合格患者中15例死亡(西酞普兰组4例,安慰剂组11例),21例未完成随访(西酞普兰组10例,安慰剂组11例)。
  • 主要结局在西酞普兰组57例(79%)中达成,在安慰剂组39例(54%)中达成(P < .001)。
  • 风险比为2(CI = 1.2-3),需治疗人数为4(CI = 2.5-8.6)。
  • 两组均未发现重大不良事件。

关键数值与推荐

  • 主要结局达标率:西酞普兰组79%(57例) vs 安慰剂组54%(39例),P < .001。
  • 风险比2(CI = 1.2-3),需治疗人数4(CI = 2.5-8.6)。

临床怎么用

  • 对非抑郁急性缺血性卒中患者,在标准治疗和物理治疗基础上可考虑使用西酞普兰20 mg每日一次以改善3个月神经功能结局。
  • 用药期间需关注安全性,本试验中未发现重大不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Ischemic stroke (IS) is one of the main causes of death and disability in the adult population, and recovery from it is a major health concern worldwide. The aim of the present study was to evaluate the effectiveness of citalopram on 3-mounth outcome of nondepressed acute IS patients. METHODS: In a randomized, placebo-controlled clinical trial, 144 patients with acute IS were studied for 3 months. In one group, the patients received oral citalopram 20 mg (once daily), and in the other group, they received placebo. All patients received standard care, including physiotherapy. Patients with depression were excluded throughout the study. The primary outcome of the study was set to a 50% reduction in the 3-month National Institutes of Health Stroke Scale compared with the baseline scores (Clinical Trial Registration URL: http://www.irct.ir ; Unique identifier: IRCT201203192150N2). RESULTS: The mean age of patients was 66.4 years. Of 144 eligible patients, 15 patients died (4 in the citalopram and 11 in the placebo group), and 21 patients did not complete the study follow-up period (10 in the citalopram and 11 in the placebo group). The primary outcome of the study was achieved in 57 patients (79%) in the citalopram and 39 patients (54%) in the placebo group ( P < .001), with risk ratio and number needed to treat of 2 (CI = 1.2-3) and 4 (CI = 2.5-8.6), respectively. No major adverse events were found in either group. CONCLUSIONS: Citalopram is a safe and tolerable medication in patients with acute IS, which could improve the outcome in these patients.

来源:Neurorehabil Neural Repair,查看原文。版权归原作者所有。

引用

  1. Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, et al. Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. Neurorehabil Neural Repair. 2017. PMID: 28454498. doi:10.1177/1545968317704902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。